related to Other mechanisms of resistance · 21Palbociclib → CCNE1/RB, CDK4, CDK4/6, CDK6, D1/CDK2, Dana Farber Institute, E1, E2, Evidence, For, Furthermore, On, Previous, Rb, Researchers, S-phase, Scientists, TGF-β, There, These
related to De novo resistance · 16Palbociclib → Brk, CDK4, CDK4/6, CDK4/6-Rb, De, E1, E2, E2F2, FAT1, Hippo, Loss, Overexpression, Previously, Rb, The, Y88
related to Resistance due to endocrine therapy · 16Palbociclib → Because CDK4/6, CDK4, CDK4/6, Certain, CHK2-mediated, ER, ESR1, For, HER2, HR, In, MutL, MutL-defective ER, PALOMA-3, PFS, Such
related to Drugs with a similar mechanism of action · 12Palbociclib → CDK4/6, Cyclin D3/CDK6, Eli Lilly, FDA, February, G1 Therapeutics, HER2-negative, HR-positive, In March, In September, Notably, Novartis
related to Legal status · 12Palbociclib → Breakthrough Therapy, Drug Administration's, ER, FDA, February, HER2, HR, In March, Priority Review, The, This, US Food
related to Mechanism of action · 12Palbociclib → CDK4, CDK4/6, CDK6, Cyclin, D-CDK4/6, G1, However, In, It, Rb, Regulation, This
related to Active clinical trials · 9Palbociclib → According, CDK4/6, III, In December, NIH National Cancer Institute, PALOMA-2, Pfizer, The, While
related to Resistance to palbociclib · 8Palbociclib → EMA-approval, FDA, For, However, OS, PALOMA-2, PFS, This
related to Economics · 7Palbociclib → According, Ibrance, In, New York, Pfizer, United States, US
related to HR+ breast cancer · 6Palbociclib → American Association, April, Cancer Research, II PALOMA-1, In, The PALOMA-3
